Single and Multiple Ascending Doses of NTX-253 in Healthy Participants and Participants With Stable Schizophrenia

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
This study will assess the safety, tolerability, and pharmacokinetics of NTX-253 following oral administration in both healthy adult participants as well as adult participants with stable schizophrenia.
Epistemonikos ID: bad971b71ef856e510a33858259bea5a3a176800
First added on: Jan 16, 2026